Photo: ALM.

The U.S. Food and Drug Administration on Monday approved and authorized for emergency use updated COVID-19 vaccines formulated to target currently circulating variants and provide better protection against serious consequences of COVID-19, including hospitalization and death. The action relates to updated mRNA vaccines for 2023-24 manufactured by Moderna and Pfizer.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and events
  • Access to other award-winning ALM websites including and

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.